Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Antares Therapeutics

Request full access

Development of precision oncology therapies, utilizing acquired discovery capabilities and a validated pipeline for patient treatments

Boston, United StatesFounded 2025Biotech & Life Sciences

About Antares Therapeutics

Antares is a biopharmaceutical entity concentrated on pioneering precision medicine, with a primary emphasis on oncology. The firm's genesis lies in the March 2025 acquisition of Scorpion Therapeutics by Lilly, enabling Antares to leverage Scorpion's established discovery capabilities and validated therapeutic pipeline.

Guidance is provided by an executive team with prior experience at Scorpion Therapeutics. Dr. Adam Friedman, with a background as a physician, scientist, and notable experience in oncology, leads as Chief Executive Officer. Amanda Valentino serves as Chief People Officer, contributing over two decades of experience in life sciences talent, human resources, and M&A.

Antares's operational strategy involves pushing scientific boundaries to develop novel therapies. The company's stated mission is to shape the future of precision medicine and deliver treatments that can transform patient lives, particularly within the oncology space. The target market encompasses advanced cancer therapeutics. The business model, characteristic of therapeutics firms, centers on research and development of new drugs, followed by clinical validation and eventual commercialization. The acquisition of its predecessor's assets by Lilly underscores the perceived value of its scientific platform and pipeline.

Source: Dealroom company data

At a glance

Status
Operational
Employees
103
Open positions
5
Dealroom signal
55.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Drug Development, Precision Medicine, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jun 2025 $177M $708M Vida Ventures · Willett Advisors · Tenmile · Vinyanshu Ventures ↗
CORPORATE SPINOUTOther financing Jan 2025 $0 — Scorpion Therapeutics ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Antares Therapeutics website traffic

Latest recorded traffic for Antares Therapeutics is 6.9K monthly website visits, up 213.6% over the last three months. Antares Therapeutics's team grew 3% over the past year.

Latest monthly visits6.9K 3-month web change+213.6% 1-year team growth+3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Antares Therapeutics in the Boston ecosystem

Live from Dealroom

The Antares Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A11 investors entered at this stage

Series B and later1 investor entered at this stage

  • Scorpion Therapeutics
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States98.9%
🇬🇧 United Kingdom1.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Antares Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Antares Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.